Disease · MONDO_0005632

acute chest syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. acute chest syndrome. Diseases, record MONDO_0005632. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005632

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: acute chest syndrome; Open Targets
Open Targets ID: MONDO_0005632; Open Targets
Other names: ACS, acute chest syndrome in sickle cell disease; Open Targets
Disease Ontology: DOID:1584; Disease Ontology
MeSH: D056586; MeSH
NCI Thesaurus: C138179; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 5 of its 20 drugs, from ClinicalTrials.gov; Open Targets

Drugs20

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TOCILIZUMAB	CHEMBL1237022	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
HYDROXYUREA	CHEMBL467	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PRASUGREL	CHEMBL1201772	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TINZAPARIN	CHEMBL6068592	Oligosaccharide	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
NITRIC OXIDE	CHEMBL1200689	Small molecule	Phase 2/3	ClinicalTrials.gov	4	4	4	Drugs and targets
ACETYLCHOLINE	CHEMBL667	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ARGININE HYDROCHLORIDE	CHEMBL1200381	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DEFIBROTIDE	CHEMBL2108396		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ENOXAPARIN	CHEMBL1201685	Oligosaccharide	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 20

See all 20 drugs

Targets20

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SERPINC1	Antithrombin-III	4	Antithrombin-III activator	Phase 2	https://conductscience.org/library/genes/462	Drugs and targets
GUCY1A1	Soluble guanylate cyclase	3	Soluble guanylate cyclase activator	Phase 2/3	https://conductscience.org/library/genes/2982	Drugs and targets
GUCY1A2	Soluble guanylate cyclase	3	Soluble guanylate cyclase activator	Phase 2/3	https://conductscience.org/library/genes/2977	Drugs and targets
GUCY1B1	Soluble guanylate cyclase	3	Soluble guanylate cyclase activator	Phase 2/3	https://conductscience.org/library/genes/2983	Drugs and targets
ADORA2A	Adenosine A2 receptor	2	Adenosine A2 receptor agonist; Adenosine A2a receptor agonist	Phase 2	https://conductscience.org/library/genes/135	Drugs and targets
ADORA1	Adenosine receptor A1	1	Adenosine A1 receptor agonist	Phase 2	https://conductscience.org/library/genes/134	Drugs and targets
ADORA2B	Adenosine A2 receptor	1	Adenosine A2 receptor agonist	Phase 2	https://conductscience.org/library/genes/136	Drugs and targets
CHRM3	Muscarinic acetylcholine receptor M3	1	Muscarinic acetylcholine receptor M3 agonist	Phase 2	https://conductscience.org/library/genes/1131	Drugs and targets
CXCR4	C-X-C chemokine receptor type 4	1	C-X-C chemokine receptor type 4 partial agonist	Phase 1	https://conductscience.org/library/genes/7852	Drugs and targets
F2	Prothrombin	1	Thrombin antagonist	Phase 2	https://conductscience.org/library/genes/2147	Drugs and targets

1 to 10 of 20

See all 20 targets

Trials16

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01794000	A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)	Phase 3	341	2016-07-27	Sickle Cell Disease	PRASUGREL	Its record names the disease	ClinicalTrials.gov
NCT01788631	A Phase II Trial of Regadenoson in Sickle Cell Anemia	Phase 2	100	2018-02-07	Sickle Cell Anemia	REGADENOSON ANHYDROUS	Its record names the disease	ClinicalTrials.gov
NCT00530270	Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease	Phase 3	12	2009-12-31	Anemia, Sickle Cell	DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov
NCT02098993	Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome	Phase 2	7	2019-07-16	Acute Chest Syndrome, Sickle Cell Disease	HEPARIN	Its record names the disease	ClinicalTrials.gov
NCT02697240	A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome	Phase 1	4	2019-04-17	Sickle Cell Disease	L-CITRULLINE	Its record names the disease	ClinicalTrials.gov
NCT05640271	Tocilizumab for Acute Chest Syndrome	Phase 2	200		Sickle Cell Disease, Acute Chest Syndrome	TOCILIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02580773	Therapeutic Anticoagulation Strategy for Acute Chest Syndrome	Phase 3	198		Anemia, Sickle Cell, Acute Chest Syndrome, Low-Molecular-Weight Heparin	TINZAPARIN	Its record names the disease	ClinicalTrials.gov
NCT03128515	Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas	Phase 3	187		Sickle Cell Anemia, Sickle Cell Disease, Malaria	HYDROXYUREA	Its record names the disease	ClinicalTrials.gov
NCT06818266	Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease	Phase 3	130		Sickle Cell Disease, Acute Chest Syndrome	TOCILIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00748423	Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study)	Phase 2/3	100		Sickle Cell Disease, Acute Chest Syndrome	NITRIC OXIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 16

See all 16 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Regadenoson Arm vs Placebo Arm: deaths from any cause	0 of 52	0 of 44	96	NCT01788631	Trial comparisons
Regadenoson Arm vs Placebo Arm: serious adverse events	14 of 52	16 of 44	96	NCT01788631	Trial comparisons
Regadenoson Arm vs Placebo Arm: Number of Participants With an Improvement in Respiratory Symptoms	10 of 49	9 of 43	92	NCT01788631	Trial comparisons
Regadenoson Arm vs Placebo Arm: Number of Participants With a Reduction in Invariant Natural-Killer T-Cell (iNKT Cell) Activation by 70% or More	21 of 49	10 of 43	92	NCT01788631	Trial comparisons
Dexamethasone vs Placebo: serious adverse events	1 of 6	0 of 6	12	NCT00530270	Trial comparisons
Unfractionated Heparin vs Standard of Care: deaths from any cause	0 of 4	0 of 3	7	NCT02098993	Trial comparisons
Unfractionated Heparin vs Standard of Care: serious adverse events	0 of 4	0 of 3	7	NCT02098993	Trial comparisons

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40209087	DERIVED	1	PubMed
32579813	DERIVED	1	PubMed
29296811	DERIVED	1	PubMed
26644172	DERIVED	1	PubMed
26431718	DERIVED	1	PubMed
21848879	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005632

GET https://conductscience.org/api/diseases/v1/MONDO_0005632/drugs

API reference For AI assistants